



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:59
Last Report Issued 06/06/2011 07:31

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1445SP
Patient ID 1445SP
Chain 11001251
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 11001251
Received 06/06/2011 07:20

Sample ID 11001251-001
Matrix Serum or Plasma
Patient Name 1445SP
Patient ID 1445SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

1445SP Dabigatran, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Dabigatran	None Detected	ng/mL	10	
Synonym(s): Pradaxa®				

Peak plasma concentrations of free dabigatran following three times daily dosing with dabigatran etexilate for seven days (n=8) were as follows:
50 mg (150 mg per day): 42 ng/mL (42% CV)
100 mg (300 mg per day): 130 ng/mL (46% CV)

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.